Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Toxicity trials of amsacrine (AMSA) and etoposide +/- azacitidine (AZ) in childhood acute non-lymphocytic leukemia (ANLL): a pilot study. Invest New Drugs 1991 May;9(2):181-4 PMID: 1714886

Pubmed ID

1714886

Abstract

Recurrent or induction therapy-resistant ANLL carries a grave prognosis. The combination of AMSA at 100 mg/M2 daily for 5 days and etoposide at 200 mg/M2 daily for the first 3 days of therapy was given to 40 patients with refractory ANLL. An additional 17 patients received those two agents plus azacitidine at a dosage of 250 mg/M2 on days 4 and 5. All three drugs were given as one-hour infusions. All patients had normal electrolyte determinations daily and were on cardiac monitors during the period of drug administration. No arrhythmias were detected in 522 doses of AMSA. Toxicities observed were primarily related to myelosuppression. Forty-nine of the 57 patients required hospitalization for suspected or proven infection. Nausea/vomiting and mucositis were the next most commonly occurring toxicities. Responses were seen in 22 patients.

Author List

Steuber CP, Holbrook T, Camitta B, Land VJ, Sexauer C, Krischer J

Author

Bruce M. Camitta MD Clinical Professor in the Medicine department at Medical College of Wisconsin




Scopus

2-s2.0-0025825531   8 Citations

MESH terms used to index this publication - Major topics in bold

Adolescent
Adult
Amsacrine
Antineoplastic Combined Chemotherapy Protocols
Azacitidine
Child
Child, Preschool
Etoposide
Female
Humans
Infant
Leukemia, Myeloid, Acute
Male
Pilot Projects
jenkins-FCD Prod-353 9ccd8489072cb19f5b9f808bb23ed672c582f41e